Kagami Y, Sakurai T, Nishio M, Narimatsu N, Saitoh A, Koshiba R, Ikeda H
Gan To Kagaku Ryoho. 1986 Dec;13(12):3523-6.
Sixteen patients with advanced or recurrent squamous cell carcinoma of the esophagus were treated with cisplatin 80 mg/m2 i.v. on day 1, methotrexate 40 mg/m2 i.v. on day 2 and peplomycin 15 mg/day 24 hours continuous subcutaneous infusion from day 2 to day 5. Each course was repeated every 3 weeks. The overall response rate was 56% (9/16) with no complete response. Of 10 patients with no prior therapy, 7 (70%) showed partial response. Toxic effects were acceptable with no fatalities, but severe nausea and vomiting (56%), transient nephrotoxicity (44%), anemia (44%), thrombocytopenia (31%) and leukocytopenia (19%) occurred. No clinical evidence of pulmonary toxicity was seen. The dose-limiting toxic effect of this regimen was myelosuppression.
16例晚期或复发性食管鳞状细胞癌患者接受如下治疗：第1天静脉注射顺铂80mg/m²，第2天静脉注射甲氨蝶呤40mg/m²，从第2天至第5天每天皮下持续输注培普利欧霉素15mg共24小时。每3周重复一个疗程。总缓解率为56%（9/16），无完全缓解。10例未接受过先前治疗的患者中，7例（70%）出现部分缓解。毒性作用可接受，无死亡病例，但出现严重恶心和呕吐（56%）、短暂性肾毒性（44%）、贫血（44%）、血小板减少（31%）和白细胞减少（19%）。未观察到肺部毒性的临床证据。该方案的剂量限制性毒性作用为骨髓抑制。
